Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enveric Biosciences filings document a biotechnology issuer focused on neuroplastogenic small-molecule drug candidates for psychiatric and neurological disorders. Its periodic and current reports address operating results, pipeline updates for EB-003 and related molecule series, intellectual-property matters, risk factors and the use of investor presentation materials in Regulation FD disclosures.
The company’s SEC record also covers capital-structure and governance matters, including registered direct and private placement financings, at-the-market offering registration, common stock, pre-funded warrants, Series G, H, I and J warrants, resale registration obligations, and Nasdaq-listed common stock. Proxy materials describe director elections, executive-compensation votes, auditor ratification, reverse stock split proposals and authorized-share proposals.
Enveric Biosciences: Schedule 13G/A showing significant warrant holdings by Lind affiliates and Jeff Easton. The filing reports 158,732 warrants held by Lind Global Fund III LP / Lind Global Partners III LLC (representing 7.76% of the class) and 161,232 warrants attributable to Jeff Easton (representing 7.87%). The ownership notes each include 79,366 Series G Warrants and 79,366 Series H Warrants; Jeff Easton is further associated with 2,500 warrants held by Lind Global Fund II. The warrants contain a conversion limitation that prevents conversion if doing so would cause beneficial ownership to exceed 9.99%.
Enveric Biosciences reported a net loss of $1.63M for the three months ended March 31, 2026, as it continues preclinical development of lead candidate EB-003 for mental health disorders. Operating expenses fell to $1.63M from $2.19M a year earlier, driven by lower R&D and G&A costs.
The company ended the quarter with $4.91M in cash and working capital of $4.91M, after raising $2.50M through a registered direct offering, concurrent private placement, and at-the-market (ATM) share sales. In April 2026 it added about $4.5M of net proceeds from another private placement and additional warrant exercises.
Despite these financings, Enveric has an accumulated deficit of $116.48M, negative operating cash flow of $2.26M in the quarter, and discloses that these factors raise substantial doubt about its ability to continue as a going concern over the next year. Management plans further capital raises and disciplined spending while advancing EB-003 toward IND-enabling studies.
Enveric Biosciences reported first quarter 2026 results and a corporate update centered on its lead neuroplastogenic candidate EB-003 and a strengthened intellectual property portfolio. EB-003 advanced through IND-enabling studies, with new preclinical data showing dual Gq and β-arrestin signaling at 5-HT2A and reduced conditioned fear in a PTSD model.
Net loss attributable to stockholders was $1.6 million, or $1.08 per basic and diluted share, for the quarter ended March 31, 2026, compared with a net loss of $2.2 million, or $14.58 per share, for the same period in 2025. Cash-on-hand was $4.9 million at March 31, 2026, and the company raised $2.8 million in gross proceeds during the quarter.
Subsequent financing events included a private placement of up to $13.9 million priced at-the-market under Nasdaq rules, with $5.0 million received at closing and up to approximately $8.9 million in potential additional warrant proceeds, plus $1.5 million from warrant exercises. As of May 15, 2026, cash was approximately $10.3 million, which management believes will fund EB-003 preclinical completion, an IND filing, and operations into the first quarter of fiscal 2027.
Enveric Biosciences, Inc. filed an 8‑K and supplemental proxy materials to correct a typographical error in its 2026 Annual Meeting proxy. The company confirms that Proposal 3 seeks approval for a reverse stock split in a range of 1‑for‑5 to 1‑for‑15, not 1‑for‑50.
The correction applies to the proxy card and notice of internet availability, while the proposal text already reflected the 1‑for‑15 maximum. The meeting remains scheduled for May 28, 2026 at 10:00 a.m. Eastern Time as a virtual event, and all other proposals and logistics are unchanged.
Enveric Biosciences is registering for resale up to 6,822,225 shares of its common stock. The registration covers (i) 98,000 issued shares and (ii) up to 6,724,225 shares issuable upon exercise of various warrants and pre-funded warrants from a April 16, 2026 private placement, including Placement Agent Warrants.
The filing states the company will not receive any proceeds from resales and that the registration satisfies registration rights granted in the Private Placement. The prospectus notes a reported Nasdaq closing price of $3.37 per share on April 21, 2026 and includes per-holder examples and Beneficial Ownership Limitations of 4.99% and 9.99%.
Enveric Biosciences, Inc. is registering the offer and resale of up to 6,822,225 shares of its common stock.
The registration covers resale by selling stockholders of (i) 98,000 shares issued in a private placement, (ii) 2,124,223 shares issuable upon exercise of pre-funded warrants, (iii) 2,222,223 shares issuable upon exercise of Series I Warrants, (iv) 2,222,223 shares issuable upon exercise of Series J Warrants, and (v) 155,556 shares issuable upon exercise of placement agent warrants. The company will receive no proceeds from resales; the selling holders may sell from time to time at prevailing market or negotiated prices. The registration relates to resale rights granted in connection with a Private Placement and includes customary beneficial ownership limits of 4.99% and 9.99% on warrant exercise; sales are subject to the plan of distribution described in the prospectus.
Enveric Biosciences, Inc. entered into a private placement financing with institutional investors, raising approximately $5.0 million in gross proceeds. The company agreed to sell 2,222,223 shares of common stock, or pre-funded warrants in lieu of shares, together with Series I and short-term Series J warrants, at a purchase price of $2.25 per share (or pre-funded warrant) and accompanying warrants.
The accompanying warrants have an exercise price of $2.00 per share and are exercisable immediately. Series I warrants will expire five years after the effective date of a resale registration statement, while Series J warrants will expire eighteen months after that date. If all Series I and Series J warrants are exercised for cash, Enveric could receive up to an additional $8.9 million in gross proceeds. The company plans to use net proceeds for product development, working capital, and general corporate purposes.
Enveric Biosciences, Inc. has called its 2026 annual stockholder meeting for May 28, 2026 at 10:00 a.m. Eastern Time, to be held exclusively online via live webcast. Stockholders of record as of March 30, 2026, when 1,887,535 shares of common stock were outstanding, may vote.
Investors are asked to elect six directors, cast an advisory “say‑on‑pay” vote on executive compensation, and extend prior approvals that give the board flexibility to effect a reverse stock split within a specified range and to increase authorized common shares from 100,000,000 to 5,000,000,000. The agenda also includes ratifying CBIZ CPAs P.C. as independent auditor for 2026 and approving potential adjournment to solicit additional proxies if needed.
The proxy details online and telephone voting procedures, broker voting rules, and how quorum and vote thresholds are calculated. It also outlines the company’s governance structure, board committees, cybersecurity oversight, and 2025 executive pay, including salary and stock‑based awards for the CEO, Chief Innovation Officer and CFO.